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Abstract
Background: The hepatitis C virus (HCV) is hyper-endemic in injecting drug users. There is also excess
HCV among non-injection drug users who smoke, snort, or sniff heroin, cocaine, crack, or
methamphetamine.
Methods: To summarize the research literature on HCV in drug users and identify gaps in knowledge,
we conducted a synthesis of the relevant research carried out between 1989 and 2006. Using rigorous
search methods, we identified and extracted data from published and unpublished reports of HCV among
drug users. We designed a quality assurance system to ensure accuracy and consistency in all phases of
the project. We also created a set of items to assess study design quality in each of the reports we
included.
Results: We identified 629 reports containing HCV prevalence rates, incidence rates and/or genotype
distribution among injecting or non-injecting drug user populations published between January 1989 and
December 2006. The majority of reports were from Western Europe (41%), North America (26%), Asia
(11%) and Australia/New Zealand (10%). We also identified reports from Eastern Europe, South America,
the Middle East, and the Caribbean. The number of publications reporting HCV rates in drug users
increased dramatically between 1989 and 2006 to 27–52 reports per year after 1998.
Conclusion: The data collection and quality assurance phases of the HCV Synthesis Project have been
completed. Recommendations for future research on HCV in drug users have come out of our data
collection phase. Future research reports can enhance their contributions to our understanding of HCV
etiology by clearly defining their drug user participants with respect to type of drug and route of
administration. Further, the use of standard reporting methods for risk factors would enable data to be
combined across a larger set of studies; this is especially important for HCV seroconversion studies which
suffer from small sample sizes and low power to examine risk factors.
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Background
Hepatitis C virus infection is hyper-endemic among injec-
tion drug user (IDU) populations [1,2], and evidence also
suggests that excess HCV infection occurs in non-injection
drug users (NIDUs) who administer heroin, cocaine, or
amphetamine by other routes, such as inhalation or
smoking [3,4]. HCV is a significant cause of morbidity
and mortality in IDUs [5,6], and a leading cause of death
among IDUs co-infected with HIV [7,8].
Once the hepatitis C virus was identified in 1989, the
availability of serologic testing for HCV antibody (anti-
HCV) led to a large number of studies of anti-HCV preva-
lence in IDUs during the 1990s. Four qualitative reviews
of HCV epidemiology in IDUs were published by 2002;
each summarized between 20 and 100 studies [1,2,9,10].
These reviews noted relatively high incidences, ranging
between 6 and 40 seroconversions per 100 person-years
(PY) of follow-up; the median incidence rates across the
four reviews were 9, 12, 16, and 16/100 PY. Anti-HCV
prevalence varied substantially, between 30 and 90%.
Some of this variation was clearly related to time at risk,
with a fairly consistent and relatively linear relationship
between number of years injecting and increasing anti-
HCV prevalence [11]. Geographic variability was also
noted in these reviews, for example, higher mean HCV
prevalence was found in studies of North American IDUs
(82%), as compared to European (67%) or Australian/
New Zealand IDUs (59%) [9]. Study year was also related
to HCV prevalence, with the gradual emergence of reports
of low-prevalence IDU samples in the literature. Alto-
gether, research suggested that HCV infection varied in
IDU populations in relation to characteristics of person,
place and time, and that insights into HCV prevention
might be obtained via a systematic, quantitative review of
available studies.
Fewer studies of HCV epidemiology have been conducted
among NIDUs than among IDUs, and the etiology of
HCV transmission in this population is not as well-under-
stood, although some believe that exposure to HCV-posi-
tive blood occurs as a result of the shared use of pipes or
straws to administer the drug [12]. Excess HCV in NIDUs
has been shown in a number of studies, with HCV preva-
lence reported between 1 and 35% [13], compared to
1.8% anti-HCV prevalence in the general population [14].
Very few NIDU studies have closely examined route of
HCV exposure, principally because they used a cross-sec-
tional design, thus weakening the interpretation of a
causal link between risk factors and incident infection.
Consistency in findings across studies, or consistency in
explanation for variation across studies, may support an
underlying causal relation between these forms of drug
use and HCV.
A recent qualitative review showed that studies of strate-
gies to prevent HCV infection in IDUs had inconsistent
results, with few examples of interventions that reduce
HCV transmission. Moreover, the majority of studies had
small sample sizes [11]. Most HCV prevention efforts thus
far have used strategies shown to decrease HIV transmis-
sion in drug users, including drug treatment, voluntary
counseling and testing, and needle exchange programs. It
appears that their effect on HCV infection may be attenu-
ated by several factors, particularly that HCV is more
highly prevalent than HIV in IDU populations so that the
probability of injecting with an HCV-infectious IDU is
greater than injection with an HIV-positive injector. Addi-
tionally, there are many more materials used to inject or
prepare drugs that may transmit HCV infection in the
injection setting. Specifically, the shared use of syringes
has been demonstrated to transmit HIV and HCV, but
other equipment used to prepare drugs for injection (drug
cookers and filtration cotton) may also transmit HCV [15-
18]. Nonetheless, despite the lack of evidence showing an
individual-level effect of various prevention strategies on
risk of HCV infection, declining HCV prevalence has been
observed in settings where comprehensive HIV preven-
tion for drug users is widely available (such as large-scale
syringe exchange and access to drug treatment) [19,20].
Altogether, the published literature suggested that a syn-
thesis of research on the epidemiology and prevention of
HCV in drug user populations was needed to examine eti-
ologic factors and drug or sexual practices that may reduce
risk of HCV transmission, and to identify gaps in the liter-
ature.
This article describes the scientific scope of this systematic
research synthesis study, the criteria used to select reports
to include in the study, the methodology used to identify
and code relevant reports, the system employed to assure
accuracy and consistency in all phases of the project, and
a summary of the study sample. Other phases of the
research synthesis study are also described. Finally, our
protocol for evaluating indicators of study quality and the
studies in our sample are summarized.
Scope of the project
We undertook the task of systematically reviewing all
studies describing the epidemiology of hepatitis C in
drug-user populations to address questions regarding fac-
tors that are associated with variability in HCV transmis-
sion. The scope of this study, "Synthesis: A meta-analysis
of HCV epidemiology and prevention in drug users" (the
HCV Synthesis Project) encompasses published and
unpublished reports from the US and abroad describing
the epidemiology of HCV infection (incidence and preva-
lence), the molecular epidemiology of HCV genotypes,
and the co-occurrence of HIV, HCV and other hepatitis
virus infections in drug users. Measures of associationBMC Medical Research Methodology 2008, 8:62 http://www.biomedcentral.com/1471-2288/8/62
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between HCV prevalence and incidence and factors such
as risk behavior and participation in prevention program-
ming are also collected. The population of interest
includes injection drug users, and non-injection drug
users of heroin, cocaine and amphetamine, because these
groups of individuals have been identified as having a
biologically plausible risk of exposure to HCV via drug
use, including percutaneous exposure (via injection drug
use) and mucous membrane exposure to HCV-positive
blood via sharing of straws or pipes used to administer
drugs (non-injection drug use). Data from IDU and NIDU
studies are analyzed separately, as they differ substantially
in the likelihood of HCV infection, and because their
drug-related risk factors are quite dissimilar. In addition,
a higher proportion of HCV infections in NIDUs vs. IDUs
may be attributable to sexual rather than drug-related
exposures, because there is less evidence to support spe-
cific drug-related transmission among NIDUs [22].
Another goal of the meta-analysis is to examine the influ-
ence of study methodology on study findings, particularly
because the descriptive epidemiology of HCV may be
strongly influenced by sampling methods, and because
study design may affect associations between various
characteristics and HCV infection. Since HCV antibody
testing is a recent development (1989), it is possible to
carry out a relatively complete synthesis covering approx-
imately 18 years (1989–2006) of research studies that
have reported incidence, prevalence and measures of asso-
ciation with HCV infection in drug users. Consistent with
the fundamental goals of meta-analysis, the purpose of
this study is to generate summary data, describe variation
in HCV epidemiology, resolve inconsistencies in findings,
and identify areas of future research.
Methods
Search strategy
Automated searches of published literature were carried
out on electronic databases (MEDLINE, PsychInfo, ERIC,
Dissertation Abstracts, Sociological Abstracts, and Current
Contents) using the following search terms: (hepatitis C
OR HCV) AND (intravenous drug abuse OR intravenous
drug use OR drug misuse OR drug addict OR injecting
drug use OR drug abuse OR IDU) AND (prevention OR
risk factor OR epidemiology OR prevalence OR incidence
OR seroprevalence OR seroincidence OR genotype OR co-
infect* OR coinfect*). We performed searches in these
electronic databases at six month intervals.
Manual search methods included the retrieval of sources
cited by seminal articles about HCV in drug-user popula-
tions, and hand searching of journals. We compiled a list
of scientific journals that have either published articles on
HCV epidemiology and prevention, or might conceivably
publish such articles based on a history of publishing arti-
cles in a similar field (HIV epidemiology, for example).
Internet searches of government websites (including local,
state and national public health websites in the US; pro-
vincial, national and ministry of health websites in other
countries; and websites for international health or drug
control organizations) were carried out to locate govern-
ment reports and unpublished surveillance estimates.
Books of abstracts and proceedings from scientific confer-
ences related to hepatitis, HIV, infectious diseases and
harm reduction were also searched for eligible reports,
using both the index of key words and by reading through
the abstracts of presentations. The NIH CRISP database
was also used to identify ongoing or recently completed
studies relevant to our meta-analysis; names of investiga-
tors identified in CRISP were periodically entered into the
electronic databases to identify publications that might
conceivably report on measures of interest. Consultants to
the study were enlisted to submit reports from their own
studies or from other studies they had learned about
through professional contacts at conferences or other
meetings; these consultants included investigators who
were carrying out research related to HCV in drug users in
the US, Europe, Asia, Africa, the Middle East and Aus-
tralia/New Zealand.
Study selection
Throughout this description of study methods, we use the
term data report to refer to published and unpublished
articles, manuscripts, personal communication, disserta-
tions, abstracts, conference presentations and book chap-
ters that are reviewed for inclusion in the study sample.
Data reports available through the end of 2006 were
included in the search; study retrieval and coding began in
August, 2004.
To be included in our study, data reports must have
included in their sample individuals who could conceiva-
bly have acquired HCV infection via administration of an
illegal drug, i.e., injection drug users, or non-injection
drug users who snort, sniff or smoke heroin, cocaine,
amphetamines or other drugs using straws or pipes. Mar-
ijuana smokers were not included in the study as there are
no epidemiologic data to indicate excess HCV in mari-
juana smokers. Similarly, those who administered
amphetamines or other illicit drugs orally (i.e., took pills)
were also excluded as there is no biologically plausible
route of HCV transmission associated with this practice.
Only those reports from which we could abstract esti-
mates of HCV prevalence, incidence, measures of associa-
tion, HIV/HCV co-infection or HCV genotype
distributions for drug users were included. Further,
reports must have given separate estimates for IDUs and
NIDUs, as these rates were expected to vary greatlyBMC Medical Research Methodology 2008, 8:62 http://www.biomedcentral.com/1471-2288/8/62
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between these two risk groups. Thus, studies that aggre-
gated IDUs and NIDUs in estimates of prevalence, inci-
dence or measures of association were not included in this
review. HCV status must have been determined by sero-
logic testing of either sera or saliva; studies that used self-
reported HCV antibody status, or those that tested for
HCV RNA without reporting the results of anti-HCV test-
ing were excluded.
Each data report could have one or more of the following
types of studies associated with it: HCV prevalence stud-
ies, HCV incidence studies, HCV genotype studies or stud-
ies of HCV co-infection with HIV or other hepatitis
viruses. Within a single report, each of these types of stud-
ies could appear and be counted as an individual study by
our definition. A report was also defined as having multi-
ple studies when epidemiologic estimates were given for
subgroups of individuals distinguished by different meth-
odology (e.g., enrollment criteria, sampling location or
sampling method) or were reported as separate samples
with different demographic characteristics or inclusion
criteria. For example, a study in IDUs that spanned five
years, and presented all their data (sample demographics
and HCV prevalence) for each year of data collection was
counted as five prevalence studies. Separating the data
into individual studies permitted the collection of sample
characteristics or methodological features associated with
the subset of subjects being examined.
Screening
A pilot study was carried out to test and develop proce-
dures for screening titles and abstracts to identify data
reports that would be eligible to be retrieved, and to esti-
mate an expected sample size (the number of data reports
that would provide data to address the aims). In October
2003, we conducted a Medline search using the keywords
mentioned above; this search retrieved 1324 articles.
Abstracts we obtained from a 5% random sample of these
articles (n = 63) and three study staff (the PI, a co-investi-
gator and a research assistant) independently pre-
screened each title and abstract. Of necessity, the criteria
for screening were broad so as to reduce the likelihood of
missing relevant studies, but it was also desirable that
screening have relatively high specificity to avoid retriev-
ing a large number of irrelevant studies.
The screening criteria were: 1) sample included IDU or
NIDU, and 2) study reported any parameters of epidemi-
ology (incidence or prevalence of HCV-antibody or HCV-
genotype), HIV/HCV co-infection, or measures of associa-
tion. For this pilot, studies must also have been written in
English. Initially, there was 80% agreement as to whether
the article should be retrieved. Screening criteria were dis-
cussed and revised to reach consensus in their application.
Beginning in August 2004, we followed the process devel-
oped in the pilot study to screen abstracts to determine
whether a report was eligible in terms of its sample and
the data it provided. For the reports whose abstracts
deemed them potentially eligible, the full text was
reviewed to determine whether it truly met our inclusion
criteria. Each abstract or report was screened for eligibility
by both a senior research assistant and the project direc-
tor. Screening sought to eliminate studies that were clearly
unrelated to the scope of the project. In cases where it
could not be definitively determined whether a report was
eligible based on reading the abstract, the full text article
was retrieved and reviewed for eligibility. When the full
text of an article was not available in English, Spanish, or
Italian, the English-language Medline abstract of the arti-
cle was used for coding.
It was common to find multiple HCV-related reports orig-
inating from a single large research project such as ALIVE,
VIDUS, CIDUS, RAVEN and many others [23-30]. Thus,
several methods were used to identify duplicate or over-
lapping reports (for example, recording study names and
searching our reference manager database for other
reports by the same author or set of authors). These poten-
tially-overlapping reports were identified but retained in
the database, as some reports included analyses of differ-
ent sets of factors or subsets of the study sample. Dupli-
cate estimates of the same parameters for the same
datasets will be excluded prior to each data analysis
project. (Figure 1 shows a decision tree of our study selec-
tion and screening process.)
Coding
The coding was carried out by senior research assistants
who had graduate training in research methodology, and
received additional training in HCV epidemiology, drug
use and meta-analytic methods. The content and structure
of the coding form was developed by reviewing those used
in other meta-analyses, for example, the CDC Prevention
Research Synthesis Project [31] and the Self-Report/Bio-
logical Measures database of Drug Use [32] The coding
form included items such as the type of study or studies
included in the body of the report (prevalence, incidence,
co-infection or genotype study), study methods (design,
inclusion criteria, recruitment method, recruitment loca-
tions, method of determining IDU/NIDU status, speci-
men type, and HCV test method), and demographics and
other characteristics of the sample such as duration of
drug use, type of drugs used, and frequency of use.
We collected all data related to HCV prevalence and inci-
dence, i.e., all numerators and denominators, including
both numbers and proportions of subjects and numbers
of person-years, to allow us to combine data from sepa-
rate studies in subsequent analyses. Anti-HCV prevalenceBMC Medical Research Methodology 2008, 8:62 http://www.biomedcentral.com/1471-2288/8/62
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HCV Meta-Analysis Project Phases Figure 1
HCV Meta-Analysis Project Phases.
Reports identified with Search Term  
Reports included if 
x Subjects were 1) injecting drug users (IDUs) 
or 2) non-injecting drug users (NIDUs)  who 
sniffed, smoked or snorted hard drugs such as 
heroin, cocaine, crack or methamphetamine 
(any duration of drug use included) and had no 
history of injection. 
x Sample fell into one of the following categories: 
IDU only samples; NIDU only samples; NIDU 
and IDU samples (HCV prevalence reported 
separately); NIDU, IDU, and non-drug user 
samples (HCV prevalence reported separately) 
x HCV status ascertained by sera or saliva test 
Reports excluded if 
x Selection of participants was based on HCV 
status 
x HCV prevalence was only given for aggregated 
group combining IDUs and NIDUs 
x NIDUs included marijuana users or users of drugs
in pill form 
x  Prevalence of HCVwas based on self report 
    
x Coding and Quality Assurance 
Procedures  
x Overlapping Data Identified  
x Research Study Quality Ratings  
x Analysis Phase  BMC Medical Research Methodology 2008, 8:62 http://www.biomedcentral.com/1471-2288/8/62
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and incidence estimates, relative risks and odds ratios
(both crude and adjusted, with their 95% confidence
intervals) were also collected in relation to sample charac-
teristics. Simple calculations were made when necessary,
and any approximations which were recorded (such as
numbers estimated from reading a figure) were marked as
such.
In some cases, the statistics recorded were simple meas-
ures of overall HCV prevalence or incidence for the entire
eligible sample, while in other cases prevalence or inci-
dence measures were reported within highly restricted
subgroups defined by a number of variables such as age,
gender, race and type of drug used. The coding form was
structured so that we could abstract both simple and com-
plicated overall estimates and sub-group comparisons,
and therefore accommodate varying degrees of complex-
ity in the data.
Thus, the coding form included fields for a number of pre-
defined categories of gender, race/ethnicity, drug use, and
risk behavior categories such as receptive and distributive
syringe sharing, the shared use of drug preparation equip-
ment (e.g., drug cooker, filtration cotton and rinse water),
the use of a syringe to divide drugs, giving or receiving
injections, injection in prison or jail, and participation in
prevention activities such as drug treatment or syringe
exchange programs. Sexual risk behavior data was also
collected, for example, number of sexual partners, unpro-
tected sex, commercial sex work and having an IDU sex
partner. For each of these risk categories describing behav-
ior, we recorded the referent time period used. There were
also fields included in the coding form intended to cap-
ture relevant data that did not conform to our preset cate-
gories.
We did not record measures such as odds ratios compar-
ing HCV prevalence or incidence in IDUs to that among
NIDUs or non-drug users, as there is clear evidence that
injection drug use is a highly potent risk behavior for HCV
acquisition, and comparisons among such populations
would not contribute new knowledge to our understand-
ing of HCV epidemiology.
Quality assurance methods
A number of strategies were used in the course of this
study to ensure reliable, valid and consistent coding of
data. For example, each data report coded by a research
assistant was subsequently reviewed for accuracy and
completeness by the Project Director and the Principal
Investigator. The coders made any necessary changes to
the coding before the report was considered complete.
Any differences of opinion among the study group mem-
bers were settled by discussion at a weekly study meeting
convened for this purpose. A study manual was developed
to guide coding and to record special cases and their reso-
lution.
Backcoding
Once a significant portion of the published data had been
coded (October 2005), the research assistants conducted
a data-coding reliability sub-study. A 10% sample of eligi-
ble coded reports was selected and re-coded by a different
coder and all discrepancies in coding were noted and
summarized. This project was undertaken to establish
whether (1) any changes in coding rules had occurred
over the course of the study, (2) there were any systematic
differences between coders or (3) there were any specific
items that may have been inconsistently coded. This reli-
ability project revealed that two items (recruitment
method and recruitment location) were inconsistently
coded. Our review of the text of the reports revealed that
variation between coders was principally due to a lack of
clarity in the presentation of this information across a sig-
nificant number of reports. Coding rules for these two var-
iables were discussed and re-defined, and these items were
back-coded for all articles.
Contacting Authors
When the text or abstract of an article or conference pres-
entation indicated that measures of interest to our study
had been collected but were not reported, we contacted
authors to request the information. These requests were
limited to simple descriptive data such as separate esti-
mates of HCV prevalence or incidence for IDUs vs.
NIDUs, or to ask for the numerator or denominator used
to estimate incidence or prevalence. We did not ask for
additional analyses of data. Authors were contacted only
if the report had been published or presented less than
five years before the coding date. Overall, we contacted
just over 100 authors, and 42% of authors we contacted
sent a reply to the request for data. Of those who replied,
70% provided data that could be included as part of the
meta-analysis.
Unpublished data
We also searched subject indexes of conference proceed-
ings (abstracts) on paper, CD-ROM or various websites.
The conferences included were annual meetings of the
American Association for the Study of Liver Diseases, the
Society for Epidemiologic Research, the American Public
Health Association, the International AIDS Society, the
National Harm Reduction Conference, the International
Conference on the Reduction of Drug Related Harm, the
College on Problems of Drug Dependence, International
Society for Infectious Diseases, and the American Socio-
logical Association. Investigators from the study also
attended a number of these conferences and collected
copies of presentations and other unpublished reports.
These abstracts were screened and the data were coded byBMC Medical Research Methodology 2008, 8:62 http://www.biomedcentral.com/1471-2288/8/62
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the same process we used for published abstracts and arti-
cles.
Substantial effort was devoted to ascertaining whether the
data in the unpublished literature duplicated any reports
that had been previously coded. This step involved cross-
checking of authors of unpublished studies against our
database and in PubMed. When matches were found, the
unpublished literature was compared to the published
report to identify whether they overlapped in terms of
location, number of subjects, and year of data collection.
Approximately half of the conference abstracts that
appeared to be codeable were subsequently eliminated
because there was a published article with overlapping
data.
Study quality measures
We followed the recommendation of the MOOSE group
[21] that meta-analyses of observational studies evaluate
certain elements of each included study indicative of their
quality. Thus, we devised a number of 'quality' items to
assess whether each study's design and implementation
was clearly explained and appropriate for the claims made
in the reports. Our scale rated several study factors likely
to affect findings of HCV prevalence, incidence and co-
infection in drug user populations, including the rigor
with which the investigators handled the problem of mis-
classification with respect to route of drug administration.
Additionally, the quality scale assessed some aspects of
the overall design and methodology of the studies, such as
sample size, reporting of demographics, presence of inclu-
sion or exclusion criteria, participation rate, adjustment
for confounding, and consistency in reporting data.
Sources of bias in study methods have been demonstrated
to account for heterogeneity in results in meta-analyses
[21].
An initial list of quality criteria was developed by the
research team to assess NIDU studies included in a paper
published by our group [13]. The quality criteria for the
IDU sample were modeled on the NIDU quality scale. A
detailed description of the NIDU quality scale can be
found in Scheinmann et al. [13]. For the complete list of
quality items used for evaluating IDU studies, see Table 1.
To determine whether the items in our quality scale were
internally consistent we performed Cronbach's alpha reli-
ability analyses using two-thirds of the data from the HCV
Table 1: Quality Measure
Quality/rigor/relevance of IDU data in studies included in HCV meta-analysis
Type of study
Issues related to studying IDUs
Was one of the stated aims to study the disease in IDUs or drug users (literature indicates interest to study HCV in IDUs)?
Sample composition (1 = non-drug users and drug users; 2 = NIDUs and IDUs; 3 = mostly IDUs; 4 = only IDUs)
Was there a method for minimizing misclassification bias (e.g., track marks or multiple interview questions)?
Methodological issues
Were dates of data collection given?
Were the selection criteria for the sample well defined and explained?
Were details of recruitment methods given?
Were details of recruitment location given?
Were there any incentives offered to the participants?
Were participation rates given for the IDU sample?
What was the participation rate?
Did data collection methods change during the study 
(e.g., recruitment method; face-to-face interviewing vs. self-administered questionnaire; testing method; etc)
Were the statistical methods used stated (for contrasts and/or measures of association)?
What was the IDU sample size tested for HCV prevalence (denominator)?
Were the number of subjects and percentages consistent?
Were age characteristics given for the IDU sample?
Were gender characteristics given for the IDU sample?
Were race/ethnic characteristics given for the IDU sample?
Were duration of injection data given for the IDU sample?
Issues related to IDU-specific behaviors/characteristics
Were there univariate analyses of prevalence?
Were there multivariate analyses of prevalence?
Was HIV prevalence given?BMC Medical Research Methodology 2008, 8:62 http://www.biomedcentral.com/1471-2288/8/62
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Synthesis Study. The 19-item scale had an alpha value of
0.73, reflecting adequate scale coherence. Removal of
items with low item-total correlations did not improve
the alpha. The distribution of the quality scale scores was
bimodal. Quality was then recoded dichotomously by
splitting between the modes.
Results
Overall, the HCV Synthesis Project has identified 2384
reports through the electronic search terms. Of those, 948
(40%) reports appeared to be eligible for coding. In most
cases of ineligible reports, it was immediately apparent
that the reports were review articles, were not reporting
any original data, or did not report any data on either
IDUs or NIDUs. 319 reports were initially classified as
codeable, but were disqualified upon closer review. The
main reasons for disqualification were 1) no HCV preva-
lence or incidence data (n = 71); 2) drug user prevalence
data aggregated, i.e., IDU and NIDU estimates were not
disaggregated or distinguished from non-drug users (n =
64); 3) sample selection based on HCV status (n = 56); 4)
results based on HCV-RNA testing alone (n = 9); and 5)
self-reported HCV status was basis for prevalence esti-
mates and no lab testing was performed (n = 26). Other
reasons for disqualification of reports were that no drug
users were included in the report; data were incomplete
for coding; the article included only a mathematical
model; or the article was a review and did not include
original data.
Thus, 629 codeable reports containing HCV prevalence
rates, incidence rates and/or genotype distribution in
injecting or non-injecting drug user populations pub-
lished between January 1989 and December 2006 were
identified. Each report contained one of more of the fol-
lowing types of information: prevalence rates, incidence
rates, genotype distributions and/or coinfection informa-
tion. Of the 629 eligible reports (some of which included
more than one of the following types of statistics), 520
reported HCV prevalence statistics, 62 reported incidence
statistics, and 118 reported genotype distribution. Fur-
ther, 345 also reported co-infection with HIV, HBV or
HAV.
Of note, a given report (e.g., a published article) may con-
tain more than one study if it provides separate data for
samples collected in different locations, time periods and/
or with different demographic data. Therefore, one report
may contain multiple studies, of either the same type (two
prevalence studies, for example) or different types (a prev-
alence study and an incidence study, for example). We
have 794 studies overall, consisting of 599 prevalence
studies, 72 incidence studies and 123 genotype studies.
Fewer than 10% of the reports included data on individu-
als meeting our definition of NIDUs. More than 95% of
all eligible reports were identified through Medline
searches. (Note that these numbers of reports do not elim-
inate overlapping reports from single studies.)
As shown in figure 2, the number of publications report-
ing HCV prevalence in IDUs rose from 1–11 reports per
year from 1989 to 1991, to 19–22 reports per year from
Number of reports per year describing HCV prevalence, incidence or genotype distribution in injection drug users in the HCV  Synthesis Project Figure 2
Number of reports per year describing HCV prevalence, incidence or genotype distribution in injection drug users in the HCV 
Synthesis Project.
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1992–1997, 33 reports in 1998, and between 27–52
reports per year after 1998.
The number of seroincidence reports in IDUs has risen
more slowly and typically remained below seven per year,
although in 2004 there were ten seroincidence reports.
The number of HCV genotype studies among IDUs has
ranged between 4 and 16 per year since 1994. The number
of reports of HCV prevalence in NIDU samples per year
has fluctuated between zero and ten. Genotype and
seroincidence in NIDUs are rarely reported, with no more
than one report in any given year (data not shown).
The majority of reports collected data from western
Europe (41%), North America (26%), Asia (11%) and
Australia/New Zealand (10%). We also identified reports
which collected data from Eastern Europe (5%), South
America (4%), the Middle East (2%) and the Caribbean
(0.3%). For a listing of the distribution of reports in the
synthesis sample by country, see Table 2.
Discussion
Electronic searches of the published literature retrieved a
substantial number of reports on the epidemiology of
HCV infection in drug users. The fact that nearly all eligi-
ble reports were discovered via Medline searches suggests
that study data are relatively accessible for a meta-analysis.
Our search of the unpublished data has so far retrieved
relatively few additional reports. This is much higher than
the 50% expected hit-rate using electronic databases [21].
Thus, exclusion of pertinent data due to publication bias
or other types of systematic omissions from our study
sample are unlikely to be of sufficient magnitude to sub-
stantially bias our findings. Funnel plots and other meth-
ods will be used to systematically examine publication
bias (to judge whether studies with small samples and low
HCV prevalence are missing from the literature).
The number of studies and reports related to HCV in injec-
tion drug users has been increasing over time, particularly
since 1995. Cross-sectional prevalence studies make up
the majority of reports we identified; these will be useful
in terms of identifying characteristics of person, place and
time associated with extreme rates of HCV prevalence.
Because cross-sectional surveys are commonly used to
characterize the epidemiology of HCV and other condi-
tions in local drug user populations, understanding
whether sampling methodology is associated with preva-
lence will help guide inferences regarding these data. The
number of seroincidence reports has grown over recent
years, and this relatively large sample (n = 62) should per-
mit greater exploration of sources of variability in sero-
conversion rates. Synthesis of co-infection studies
reporting HCV, HBV and HIV infection rates will provide
insight into the joint occurrence of these infections and
Table 2: Number of Reports per Country
Geographical Location of Studies in HCV Synthesis Project
Country Number of Reports Percentage
Argentina 4 0.6%
Australia 56 8.9%
Austria 8 1.3%
Bangladesh 4 0.6%
Belgium 7 1.1%
Bosnia and Herzegovina 1 0.2%
Brazil 20 3.2%
Bulgaria 2 0.3%
Canada 22 3.5%
China 17 2.7%
Croatia 2 0.3%
Czech Republic 5 0.8%
Denmark 3 0.5%
Egypt 1 0.2%
England 20 3.2%
Estonia 1 0.2%
Finland 2 0.3%
France 22 3.5%
Georgia 3 0.5%
Germany 19 3.0%
Greece 9 1.4%
Haiti 1 0.2%
Hong Kong 2 0.3%
Hungary 1 0.2%
Iceland 3 0.5%
India 7 1.1%
Iran 3 0.5%
Ireland 13 2.1%
Israel 2 0.3%
*Italy 47 7.5%
Japan 4 0.6%
Lebanon 2 0.3%
Malaysia 4 0.6%
Martinique 1 0.2%
Mexico 1 0.2%
Multiple 3 0.5%
Nepal 4 0.6%
New Zealand 8 1.3%
Norway 4 0.6%
Pakistan 1 0.2%
Philippines 1 0.2%
Poland 3 0.5%
Portugal 1 0.2%
Russia 11 1.8%
Saudi Arabia 4 0.6%
Scotland 20 3.2%
Slovenia 1 0.2%
*Spain 46 7.3%
Sweden 12 1.9%
Switzerland 7 1.1%
Syria 1 0.2%
Taiwan 9 1.4%
Thailand 13 2.1%
The Netherlands 10 1.6%
UK 3 0.5%
USA 139 22.2%
Uzbekistan 3 0.5%
Vietnam 3 0.5%
Wales 1 0.2%
* Since we coded articles in Spanish and Italian, as well as English 
language articles, reports from Italy and Spain may be over-
represented in comparison to reports from other countries outside 
the US.BMC Medical Research Methodology 2008, 8:62 http://www.biomedcentral.com/1471-2288/8/62
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factors associated with similarities in their epidemiology
in drug users. Co-infection data and HCV genotype infor-
mation will be relevant to health care planning, particu-
larly the treatment of HIV/HCV co-infection and HCV
mono-infection in drug users.
The scope and aims of the HCV Synthesis Project differ
from typical meta-analyses which seek to combine effect
sizes arising from studies of interventions or treatments.
Nonetheless, we adapted standard approaches to meta-
analysis [33] to synthesize parameters of epidemiology.
The challenges we encountered in collecting and coding
these data include lack of standard reporting of risk factor
data, overlapping publication of data, and missing details
on study methodology. One notable finding from our
summary of the HCV Synthesis Project data is that future
research reports can enhance their contributions to our
understanding of HCV epidmiology by clearly defining
their drug user participants with respect to type of drug
and route of administration, and by analyzing and report-
ing data separately in injection and non-injection users of
drugs. (Figure 3 summarizes recommendations for future
research on HCV among drug user populations.)
Had more studies disaggregated IDU and NIDU data, our
sample of NIDU studies would have potentially doubled
(provided that the NIDU sample fit our definition of non
injection drug users who sniff, snort, or smoke hard
drugs). Unfortunately, a large number of studies that were
ineligible for this reason were from developing countries
for which HCV data are scarce. The use of standard report-
ing methods, as promulgated by MOOSE [21], would ena-
ble data to be combined across a larger set of studies; this
is especially important for HCV seroconversion studies
which suffer from small sample sizes and low power to
examine risk factors. MOOSE developed recommenda-
tions for meta-analyses of observational studies of inter-
ventions and etiologic factors. In general, we have
followed their recommendations adapted to our specific
research questions and the field of drug use related
research. For example, we did use broad inclusion criteria
which has yielded a large sample size.
Despite the fact that meta-analysis is traditionally used to
combine results from randomized studies, such as rand-
omized control trials, the use of meta-analysis to combine
results from observational studies is becoming wide-
spread because of the many issues in public health which
cannot be studied without the use of observational
designs. In order to apply meta-analytic techniques to sets
of observational studies, it is necessary to develop homo-
geneous subsets, so that confounding factors do not
overly influence the meta-analytic results [35]. Heteroge-
neous sets of studies may be systematically described and
sources of confounding or bias can be elucidated.
Conclusion
Overall, we believe it will be essential to use meta-analysis
to address outstanding questions regarding HCV preven-
tion. Because individual studies have failed to find evi-
dence of specific protective factors for HCV in drug users
(especially IDUs) and the etiology of HCV transmission in
NIDUs remains somewhat vague, meta-analysis may
prove to be highly useful in addressing endemic HCV in
drug users. For instance, combining data across serocon-
version studies would substantially increase the ability to
detect consistent and statistically significant risk factors.
Additionally, identifying in more detail the relationship
between HCV prevalence and incidence and number of
years injecting is essential for honing and targeting pre-
vention efforts [34].
For the HCV Synthesis Project, the data set is complete
and data analysis is in process. A report on HCV in NIDUs
is published [13]; a preliminary analysis of the relation-
ship of gender, duration and age to HCV in IDUs is in
press [34]; and a report on the relationship of racial and
ethnic status to HCV in IDUs is in preparation. Future
Recommendations for future research on HCV in drug-user  populations Figure 3
Recommendations for future research on HCV in drug-user 
populations.
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analyses in preparation will focus on complex questions
of variability in HCV prevalence and incidence in injec-
tion drug users. It is anticipated that this study will help to
summarize the state of HCV knowledge, identify new
research questions or those that need additional confir-
mation, and may point towards promising HCV preven-
tion strategies.
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